Balaji Prasad
Stock Analyst at Barclays
(3.08)
# 1,236
Out of 4,876 analysts
147
Total ratings
43.55%
Success rate
0.22%
Average return
Main Sectors:
Stocks Rated by Balaji Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EOLS Evolus | Maintains: Overweight | $22 → $25 | $9.29 | +169.11% | 8 | Mar 5, 2025 | |
| AMRX Amneal Pharmaceuticals | Maintains: Overweight | $10 → $11 | $8.18 | +34.56% | 5 | Mar 3, 2025 | |
| PCRX Pacira BioSciences | Maintains: Overweight | $17 → $24 | $23.86 | +0.61% | 9 | Feb 28, 2025 | |
| VTRS Viatris | Maintains: Underweight | $12 → $9 | $9.06 | -0.61% | 8 | Feb 28, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $190 → $200 | $108.54 | +84.26% | 10 | Feb 27, 2025 | |
| ELAN Elanco Animal Health | Maintains: Overweight | $20 → $19 | $14.45 | +31.53% | 13 | Feb 26, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Overweight | $62 → $60 | $41.00 | +46.34% | 5 | Feb 26, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $242 → $244 | $156.85 | +55.56% | 16 | Feb 14, 2025 | |
| OGN Organon & Co. | Maintains: Overweight | $26 → $24 | $9.97 | +140.72% | 2 | Feb 14, 2025 | |
| PAHC Phibro Animal Health | Maintains: Underweight | $20 → $22 | $25.67 | -14.30% | 8 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $481 → $520 | $534.99 | -2.80% | 9 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $16.85 | +54.35% | 12 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $150 → $160 | $115.26 | +38.82% | 15 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $17 | $15.11 | +12.51% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $18 | $9.30 | +93.55% | 5 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $10 | $3.56 | +180.89% | 2 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7 | $0.77 | +813.84% | 7 | Oct 23, 2023 |
Evolus
Mar 5, 2025
Maintains: Overweight
Price Target: $22 → $25
Current: $9.29
Upside: +169.11%
Amneal Pharmaceuticals
Mar 3, 2025
Maintains: Overweight
Price Target: $10 → $11
Current: $8.18
Upside: +34.56%
Pacira BioSciences
Feb 28, 2025
Maintains: Overweight
Price Target: $17 → $24
Current: $23.86
Upside: +0.61%
Viatris
Feb 28, 2025
Maintains: Underweight
Price Target: $12 → $9
Current: $9.06
Upside: -0.61%
Jazz Pharmaceuticals
Feb 27, 2025
Maintains: Overweight
Price Target: $190 → $200
Current: $108.54
Upside: +84.26%
Elanco Animal Health
Feb 26, 2025
Maintains: Overweight
Price Target: $20 → $19
Current: $14.45
Upside: +31.53%
Tarsus Pharmaceuticals
Feb 26, 2025
Maintains: Overweight
Price Target: $62 → $60
Current: $41.00
Upside: +46.34%
Zoetis
Feb 14, 2025
Maintains: Overweight
Price Target: $242 → $244
Current: $156.85
Upside: +55.56%
Organon & Co.
Feb 14, 2025
Maintains: Overweight
Price Target: $26 → $24
Current: $9.97
Upside: +140.72%
Phibro Animal Health
Feb 10, 2025
Maintains: Underweight
Price Target: $20 → $22
Current: $25.67
Upside: -14.30%
Feb 4, 2025
Maintains: Overweight
Price Target: $481 → $520
Current: $534.99
Upside: -2.80%
Jan 30, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $16.85
Upside: +54.35%
Dec 16, 2024
Maintains: Overweight
Price Target: $150 → $160
Current: $115.26
Upside: +38.82%
Nov 6, 2024
Maintains: Overweight
Price Target: $17 → $17
Current: $15.11
Upside: +12.51%
Jul 25, 2024
Maintains: Overweight
Price Target: $22 → $18
Current: $9.30
Upside: +93.55%
Oct 23, 2023
Maintains: Equal-Weight
Price Target: $2.5 → $10
Current: $3.56
Upside: +180.89%
Oct 23, 2023
Maintains: Overweight
Price Target: $8 → $7
Current: $0.77
Upside: +813.84%